Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Public-academic partnerships: a program to improve the quality of antipsychotic prescribing in a community mental health system.

Literature DB >> 21885576

Public-academic partnerships: a program to improve the quality of antipsychotic prescribing in a community mental health system.

Mary F Brunette¹, Alexander de Nesnera, Karin Swain, Erik G Riera, Doris Lotz, Stephen J Bartels.

Abstract

State mental health authorities can use public-academic partnerships to create professional roles in which leaders can track trends, identify problems, and carry out quality improvement projects to address key issues. Leaders with positions in both academic institutions and state mental health authorities ensure access to resources, technical expertise, and key relationships to improve quality. The authors describe a public-academic partnership in New Hampshire and a quality improvement program it carried out. The program encourages providers at community mental health centers to adopt prescribing practices that limit the cardiometabolic side effects of antipsychotic medicines.

Entities: Disease Gene Species

Mesh：

Substances：
Antipsychotic Agents

Year: 2011 PMID： 21885576 PMCID： PMC3780400 DOI： 10.1176/appi.ps.62.9.1004

Source DB: PubMed Journal: Psychiatr Serv ISSN： 1075-2730 Impact factor: 3.084

19 in total

1. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements.

Authors: Michael R Law; Dennis Ross-Degnan; Stephen B Soumerai
Journal: Psychiatr Serv Date: 2008-05 Impact factor: 3.084

2. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.

Authors: Joel F Farley; Richard R Cline; Jon C Schommer; Ronald S Hadsall; John A Nyman
Journal: Clin Ther Date: 2008-08 Impact factor: 3.393

3. Predictors of antipsychotic withdrawal or dose reduction in a randomized controlled trial of provider education.

Authors: K G Meador; J A Taylor; P B Thapa; R L Fought; W A Ray
Journal: J Am Geriatr Soc Date: 1997-02 Impact factor: 5.562

Review 4. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Authors: John W Newcomer
Journal: CNS Drugs Date: 2005 Impact factor: 5.749

Review 5. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors: Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal: Schizophr Bull Date: 2009-12-02 Impact factor: 9.306

6. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change.

Authors: Stephen B Soumerai; Fang Zhang; Dennis Ross-Degnan; Daniel E Ball; Robert F LeCates; Michael R Law; Tom E Hughes; Daniel Chapman; Alyce S Adams
Journal: Health Aff (Millwood) Date: 2008-04-01 Impact factor: 6.301

Review 7. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients.

Authors: Christoph U Correll
Journal: Int Rev Psychiatry Date: 2008-04

Public-academic partnerships: a program to improve the quality of antipsychotic prescribing in a community mental health system.

1. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements.

2. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.

3. Predictors of antipsychotic withdrawal or dose reduction in a randomized controlled trial of provider education.

Review 4. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Review 5. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

6. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change.

Review 7. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients.

Review 8. Continuing education meetings and workshops: effects on professional practice and health care outcomes.

Review 9. Educational outreach visits: effects on professional practice and health care outcomes.

10. Medicaid prescription drug policies and medication access and continuity: findings from ten states.

1. Use of Academic Detailing With Audit and Feedback to Improve Antipsychotic Pharmacotherapy.

2. Significance and Factors Associated with Antipsychotic Polypharmacy Utilization Among Publicly Insured US Adults.

3. Purpose Formulation, Coalition Building, and Evidence Use in Public-Academic Partnerships: Web-Based Survey Study.